-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the Zhitong Finance App, Goli Pharmaceutical-B (01672.HK) issued an announcement. Goli has submitted a new drug clinical trial application (IND) for ASC36_37o FDC to the US Food and Drug Administration (FDA) to treat obesity. ASC36_37O FDC is a weekly oral fixed-dose combination (FDC) tablet of the insulin agonist polypeptide ASC36 and GLP-1R/GIPR/GCGR tri-target agonist polypeptide ASC37.

Zhitongcaijing·11/17/2026 09:09:08
Listen to the news
According to the Zhitong Finance App, Goli Pharmaceutical-B (01672.HK) issued an announcement. Goli has submitted a new drug clinical trial application (IND) for ASC36_37o FDC to the US Food and Drug Administration (FDA) to treat obesity. ASC36_37O FDC is a weekly oral fixed-dose combination (FDC) tablet of the insulin agonist polypeptide ASC36 and GLP-1R/GIPR/GCGR tri-target agonist polypeptide ASC37.